Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.41 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 1/20 | 0.33 |
| ▸ | FURIN | P09958 | 2/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19708234 | 1.00 | FAP (0.41) | FAPMAP1LC3BOPRK1SIRT2SIRT1 | |
| SCHEMBL20467807 | 1.00 | FAP (0.41) | FAPMAP1LC3BOPRK1SIRT2SIRT1 | |
| SCHEMBL23353477 | 0.98 | FAP (0.40) | FAPMAP1LC3BOPRK1SIRT2SIRT1 | |
| SCHEMBL23191581 | 0.95 | FAP (0.42) | FAPMAP1LC3BSIRT2SIRT1SIRT5 | |
| SCHEMBL24224695 | 0.95 | FAP (0.42) | FAPMAP1LC3BSIRT2SIRT1SIRT5 | |
| SCHEMBL24829341 | 0.95 | FAP (0.40) | FAPMAP1LC3BOPRK1SIRT5 | |
| SCHEMBL22668658 | 0.94 | FAP (0.41) | FAPMAP1LC3BOPRK1SIRT2SIRT1 | |
| SCHEMBL18908999 | 0.93 | FAP (0.43) | FAPMAP1LC3BSIRT2SIRT1SIRT5 | |
| SCHEMBL21119089 | 0.93 | FAP (0.43) | FAPMAP1LC3BSIRT2SIRT1SIRT5 | |
| SCHEMBL24477196 | 0.93 | FAP (0.42) | FAPMAP1LC3BOPRK1SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | NOVARTIS AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230037682-A1 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | NOVARTIS AG (CH) | 2023-02-09 | — | — | US | disclosed |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-11161911-B2 | Anti-glyco-MUC1 antibodies and their uses | GO THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2021195513-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISORDERS | NOVARTIS AG (CH) | 2021-09-30 | — | — | WO | disclosed |
| US-20200215200-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2020-07-09 | — | — | US | disclosed |
| US-10383948-B2 | Anti-cMet antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190119400-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2019-04-11 | — | — | US | disclosed |
| US-10195209-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10188660-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-10011657-B2 | Anti-CS1 antibodies and antibody drug conjugates | ABBVIE BIOTHERAPEUTICS INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2017-12-07 | — | — | US | disclosed |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | CD44, SIGLEC7, SIGLEC9 | FAP 1650/4885MAP1LC3B 2719/4885OPRK1 3461/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | FAP 575/4885MAP1LC3B 4272/4885OPRK1 2715/4885 |
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885MAP1LC3B 729/4885OPRK1 3286/4885 |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | CD2, CD22, CD2BP2 | FAP 1135/4885MAP1LC3B 949/4885OPRK1 4190/4885 |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885MAP1LC3B 729/4885OPRK1 3286/4885 |
| US-20200215200-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | FAP 3032/4885MAP1LC3B 1941/4885OPRK1 3214/4885 |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | FAP 4569/4885MAP1LC3B 729/4885OPRK1 3286/4885 |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | FAP 3032/4885MAP1LC3B 1941/4885OPRK1 3214/4885 |
| US-10011657-B2 | Anti-CS1 antibodies and antibody drug conjugates | CD47, CSGALNACT1, CSE1L | FAP 4279/4885MAP1LC3B 1804/4885OPRK1 4782/4885 |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | CD2, CD2BP2, CD22 | FAP 1899/4885MAP1LC3B 3734/4885OPRK1 3426/4885 |
| US-10383948-B2 | Anti-cMet antibody drug conjugates and methods for their use | MMAB, HNMT, SHMT1 | FAP 3032/4885MAP1LC3B 1941/4885OPRK1 3214/4885 |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | FAP 1009/4885MAP1LC3B 3165/4885OPRK1 4504/4885 |
| US-20230037682-A1 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | CD2, CD4, CD14 | FAP 1416/4885MAP1LC3B 2525/4885OPRK1 3521/4885 |
| US-11161911-B2 | Anti-glyco-MUC1 antibodies and their uses | MUC1, SIGLEC7, SIGLEC9 | FAP 1009/4885MAP1LC3B 3165/4885OPRK1 4504/4885 |
| US-20190119400-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | FAP 1009/4885MAP1LC3B 3165/4885OPRK1 4504/4885 |
| US-10188660-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | FAP 4569/4885MAP1LC3B 729/4885OPRK1 3286/4885 |
| US-10195209-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | FAP 4569/4885MAP1LC3B 729/4885OPRK1 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.